Key Drivers
- Strong cash position
- Zero revenue
- Negative free cashflow
AIAI Summary
MBX has transitioned from a cash‑constrained dilution risk to a well‑funded, late‑stage developer—making on‑time clinical execution (Q3‑2026 Phase‑3 start for canvuparatide and the Q2 one‑year BMD readout) the primary value driver to watch alongside quarterly burn vs. guidance. Key action: monitor those clinical milestones and runway metrics closely, and consider pacing entries or using the ~$27.9 support as a tactical risk level ahead of these binary catalysts.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash position
- •Zero revenue
- •Negative free cashflow
MBX retains very strong liquidity and minimal leverage but generated no revenue, incurred heavy R&D-driven operating losses and negative free cash flow, causing material cash burn despite a large asset base.
Price Behavior
Key Price Behavior Insights:
- •Downtrend momentum
- •Near‑term support
- •Elevated volatility
MBX is in a short‑term downtrend: price fell ~17.6% over the last month to $28.68, trading ~8% below the last‑month average (~$31.20) with immediate downside limited by support near $27.94–$27.95 but facing resistance at $31.30–$33.00 and a stronger supply zone near $36.73–$36.75.
Rapid ~17.6% drop from $34.79 to $28.68 over the last month, increasing follow‑through selling risk
Sentiment & News
Key News Insights:
- •Cash runway
- •Phase 3 on‑track
- •Manufacturing upgrade
MBX Biosciences reports solid cash runway and regulatory momentum with a Q3‑2026 Phase 3 start target and multiple near‑term development nominations while Microbix highlights manufacturing improvements.
These developments materially de‑risk MBX's clinical timeline and create near‑term catalyst visibility that could support the stock if milestones are met
Similar Companies in Healthcare
Other companies in the same sector with AI ratings